Liquid biopsy for early detection of lung cancer

Current Opinion in Oncology

Volumn 29, Issue 1, 2017, Pages 73-78

  Hofman, Paul ^a,b,c  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Circulating tumor cells; free circulating DNA; liquid biopsy; lung cancer; screening

Indexed keywords

DNA; MICRORNA; NUCLEIC ACID; PROTEIN; TUMOR MARKER;

BIOPSY TECHNIQUE; BLOOD; CANCER SCREENING; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; HUMAN; LIQUID BIOPSY; LUNG CANCER; PLASMA; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; BIOPSY; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

BIOMARKERS, TUMOR; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS;

EID: 85007211490     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000343     Document Type: Review

References (61)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30.
2. Gadgeel SM. Personalized therapy of nonsmall cell lung cancer (NSCLC). Adv Exp Med Biol 2016; 890:203-222.
3. Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2016; 28:122-129.
4. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med 2015; 191:1166-1175.
5. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160:330-338.
6. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395-409.
7. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012; 21:308-315.
8. Patz EF Jr, Pinsky P, Gatsonis C, et al. NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174:269-274.
9. Veronesi G, Maisonneuve P, Spaggiari L, et al. Diagnostic performance of low-dose computed tomography screening for lung cancer over five years. J Thorac Oncol 2014; 9:935-939.
10. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016; 193:542-551.
11. Veronesi G. Lung cancer screening: the European perspective. Thorac Surg Clin 2015; 25:161-174.
12. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148:349-361.
13. Buder A, Tomuta C, Filipits M. The potential of liquid biopsies. Curr Opin Oncol 2016; 28:130-134.
14. Hofman P, Popper HH. Pathologists and liquid biopsies: to be or not to be? Virchows Arch 2016. [Epub ahead of print]
15. 15. Ilie M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016; 5:420-423.
16. Mino-Kenudson M. Cons: can tissue biopsy be replaced by liquid biopsy-the US experience. Transl Lung Cancer Res 2016; 5:424-427.
17. Lancet Oncology. Liquid cancer biopsy: the future of cancer detection? Lancet Oncol 2016; 17:123.
18. Strotman LN, Millner LM, Valdes R Jr, Linder MW. Liquid biopsies in oncology and the current regulatory landscape. Mol Diagn Ther 2016; 20:429-436.
19. Crosbie PA, Shah R, Summers Y, et al. Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Transl Lung Cancer Res 2013; 2:382-397.
20. Hofman VJ, Ilie M, Hofman PM. Detection and characterization of circulating tumor cells in lung cancer: why and how? Cancer Cytopathol 2016; 124:380-387.
21. Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in nonsmall cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014; 2:107.
22. Ilie M, Hofman V, Long-Mira E, et al. 'Sentinel' circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014; 9:e111597.
23. Montani F, Marzi MJ, Dezi F, et al. miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst 2015; 107:djv063.
24. Hofman V, Ilie M, Long E, et al. Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med 2014; 14:440-456.
25. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011; 17:827-835.
26. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for nonsmall-cell lung carcinoma: comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method. Int J Cancer 2011; 129:1651-1660.
27. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30:525-532.
28. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with nonsmall cell lung cancer using epithelial marker-dependent and-independent approaches. J Thorac Oncol 2012; 7:306-315.
29. Hofman V, Long E, Ilie M, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for nonsmall cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012; 23:30-38.
30. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108:3713-3718.
31. Gao X, Wang Y, Zhao H, et al. Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. Oncotarget 2016; doi: 10.18632/oncotarget.11198. [Epub ahead of print]
32. Gyoba J, Shan S, Roa W, Bédard EL. Diagnosing lung cancers through examination of micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci 2016; 17:ii:E494.
33. Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016; 17:ii:E627.
34. Ma J, Lin Y, Zhan M, et al. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab Invest 2015; 95:1197-1206.
35. Nadal E, Truini A, Nakata A, et al. A novel serum 4-microRNA signature for lung cancer detection. Sci Rep 2015; 5:12464.
36. Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as noninvasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 2013; 8:e54596.
37. Wozniak MB, Scelo G, Muller DC, et al. Circulating microRNAs as noninvasive biomarkers for early detection of nonsmall-cell lung cancer. PLoS One 2015; 10:e0125026.
38. Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage nonsmall cell lung cancer. PLoS One 2016; 11:e0153046.
39. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014; 32:768-773.
40. Becker N, Lockwood CM. Preanalytical variables in miRNA analysis. Clin Biochem 2013; 46:861-868.
41. Mi S, Zhang J, Zhang W, Huang RS. Circulating microRNAs as biomarkers for inflammatory diseases. Microrna 2013; 2:63-71.
42. Xu J, Zhao J, Evan G, et al. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl) 2012; 90:865-875.
43. Chian CF, Hwang YT, Terng HJ, et al. Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages. Oncotarget 2016; doi: 10.18632/oncotarget. 10558. [Epub ahead of print]
44. Qi P, Zhou XY, Du X. Circulating long noncoding RNAs in cancer: current status and future perspectives. Mol Cancer 2016; 15:39.
45. Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine 2016; piiS2352-3964:30289-30294.
46. Hirales Casillas CE, Flores Fernández JM, Padilla Camberos E, et al. Current status of circulating protein biomarkers to aid the early detection of lung cancer. Future Oncol 2014; 10:1501-1513.
47. Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in nonsmall cell lung cancer. Lung Cancer 2015; 90:128-134.
48. Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissuespecific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci USA 2016; 113:E1826-E1834.
49. Tomasetti M, Amati M, Neuzil J, Santarelli L. Circulating epigenetic biomarkers in lung malignancies: from early diagnosis to therapy. Lung Cancer 2016; S0169-5002:30350-30356.
50. Levine ME, Hosgood HD, Chen B, et al. DNA methylation age of blood predicts future onset of lung cancer in the women's health initiative. Aging (Albany NY) 2015; 7:690-700.
51. Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci 2015; 2:13.
52. Ajona D, Pajares MJ, Corrales L, et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 2013; 105:1385-1393.
53. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011; 22:383-389.
54. Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT1lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer 2014; 83:51-55.
55. Vachani A, Pass HI, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J ThoracOncol 2015; 10:629-637.
56. Louis E, Adriaensens P, Guedens W, et al. Detection of lung cancer through metabolic changes measured in blood plasma. J Thorac Oncol 2016; 11:516-523.
57. Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, et al. A novel epigenetic signature for early diagnosis in lung cancer. Clin Cancer Res 2016; 22:3361-3371.
58. Silvestri GA, Vachani A, Whitney D, et al., AEGIS Study Team. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med 2015; 373:243-251.
59. Taivans I, Bukovskis M, Strazda G, Jurka N. Breath testing as a method for detecting lung cancer. Expert Rev Anticancer Ther 2014; 14: 121-123.
60. Pass HI, Beer DG, Joseph S,Massion P. Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. Thorac Surg Clin 2013; 23:211-224.
61. Lokhandwala T, Bittoni MA, Dann RA, et al. Costs of diagnostic assessment for lung cancer: a medicare claims analysis. Clin Lung Cancer 2016; pii: S1525-7304(16)30186-3. [Epub ahead of print]